Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$13.1MCash, Jun 2026
8moCash Runway (est.)
+21%Share Count, 1 Year
Follow GANX by emailGet an email when GANX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GANX, unsubscribe in one click. Privacy
📣 What GANX Says Is Next
Q4 2026 · “Final results from Phase 1b clinical study of rexaceract expected in Q4 2026.”
Company press release, Aug 11, 2026 · SEC filing
Q4 2026 · “Results from Phase 1b clinical study of GT-02287 expected in Q4 2026 .”
Company press release, May 11, 2026 · SEC filing
4Q26 · “Results from Phase 1b clinical study of GT-02287 expected in 4Q26.”
Company press release, Mar 26, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
💰 Cash Runway & Dilution Risk
GANX reported $13.1M in cash and short-term investments (as of Jun 30, 2026) and used about $4.7M/quarter in operations, an estimated runway of 8.3 months at that rate (BioRadar estimate, not company guidance).
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GANX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.